Multiple new NMIBC therapies offer bladder preservation hope: cretostimogene shows 46% 1-year response with minimal toxicity.
Bladder Cancer at a Crossroads: Sequencing, Biomarkers, and Combination Therapy Read More »
FDA approves mitomycin (Zusduri) for recurrent low-grade NMIBC: 78% complete response, 79% maintain response ≥12 months in ENVISION trial.
Total neoadjuvant therapy with FLOT may optimize outcomes, but ctDNA could guide personalized treatment decisions.
Making Sense of FLOT, Durvalumab, and the Role of Real-World Tumor Biology Read More »
FDA approves sunvozertinib for NSCLC with EGFR exon20 insertion mutations – first oral targeted therapy achieving 46% response rate.
FDA Greenlights Oral Therapy for NSCLC With EGFR Exon20 Insertion Mutations Read More »
68Ga-NY104 PET/CT shows better diagnostic efficacy than 18F-FDG PET/CT in patients with metastatic clear cell renal cell carcinoma.
68Ga-NY104 PET/CT Outperforms 18F-FDG PET/CT in Metastatic ccRCC Read More »
CR rates greater than 80% achieved with TAR-200 device – first time we’ve seen rates this high in BCG-unresponsive NMIBC patients.
XBCM urinary biomarker test achieves 91% sensitivity and 99% NPV while reducing cystoscopy burden by 56% in high-grade NMIBC surveillance.
Urinary Biomarker Test XBCM Reduces Cystoscopy in High-Grade NMIBC Surveillance Read More »
